Nadler Jeffrey P, Phillips Michael C
Tampa General Hospital, Department of Infectious Diseases, G318, 2 Columbia Drive, Tampa, FL 33606, USA.
Curr Infect Dis Rep. 2005 May;7(3):221-226. doi: 10.1007/s11908-005-0038-5.
Since the introduction of zidovudine 18 years ago, the treatment of HIV has been rapidly evolving. Current therapies target the HIV retrovirus successfully but contain their own perils. Active therapies with reduced adverse effects and long-term activity in the presence of, or reduced susceptibility to, antiviral resistance continue to be needed. Furthermore, more convenient agents that may facilitate adherence to therapy are a goal of new drug development. This review addresses these clinical needs, with a discussion of several new drugs currently in the clinical trial pipeline.
